RESPONSE SCIENTIFIC, INC.® (RSI) is a Research Biotechnology Corporation. RSI's mission is to improve people's lives through innovative research leading to revolutionary healthcare products and treatments. For more than a decade the Company has maintained a close working relationship with a team of the country’s leading biochemists and biomedical engineers. Currently, the Company is entering the commercialization stage for FDA and non-FDA regulated healthcare products, which represent a multibillion-dollar business. RSI has the exclusive option for the worldwide rights to a novel patent pending technology titled Modified Alginate Hydrogels for Therapeutic Agents (USPTO Pending #15/606/769 & PCT/US/17/34748) and a second filing titled Modified Carbohydrates, Compositions Comprising the Same, and Methods of Making and Using the Same (PCT/US/17/40283). Designed for oral delivery, the technology revolutionizes the way prescription and non-prescription medications, veterinary medicines, probiotics, dietary supplements and other substances are protected from damaging stomach acids and enzymatic action. It also creates an entirely new mechanism of extended time release. Mr. Gregory D. Webster Chairman, Chief Executive Officer and President Dr. Emmanuel C. Opara Ph.D. Chairman of Scientific Advisory Board and Vice President of Technology Dr. James J. Balija Ph.D. Vice President, Corporate Secretary and Director Bryan K. Finch Vice President of Corporate Responsibility and Director Mr. Dirk Van Wijk Vice President of Canadian Operations and Sales & Marketing Manager